Abstract
Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80–90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.
Highlights
Literature searchThis living systematic review follows the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline (Supplement Part S1)
Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people
In December 2020, the Robert Koch Institute (RKI), in collaboration with the National Immunisation Technical Advisory Groups (NITAGs) network coordinated by the European Centre for Disease Prevention and Control (ECDC) initiated a living systematic review on the VE and safety of European Union (EU)-licensed COVID-19 vaccines (PROSPERO registration: CRD42020208935)
Summary
This living systematic review follows the recommendations of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guideline (Supplement Part S1). Of the 30 studies, 26 investigated the efficacy/effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections, based on reports of number of symptomatic and asymptomatic PCR-positive individuals [3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,22,23,24,25,26,27,28,29,30,31] (Table 1). The other studies had a cohort design and investigated Comirnaty or Comirnaty and COVID-19 vaccine Moderna using either hospital, insurance or surveillance data In five of these six studies, VE against asymptomatic infection after one dose of Comirnaty or COVID-19 vaccine Moderna ranged from 36% to 79%.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
